
ALT Decompensated cirrhosis is not always permanent: curing or controlling the underlying cause can return patients to a compensated state, especially when disease is less severe and treatment starts early. This review defines recompensation, summarizes its natural history and clinical implications, and outlines considerations for clinical trials.

ALT Two figures showing the effect of retatrutide on body weight. Panel A shows the percent change in body weight from baseline to week 80 (controlled for type I error). Panel B shows the percentage of patients with reductions in body weight of 15% or more and 30% or more (controlled for type I error), along with the percentage of patients who reached the body-mass index targets of less than 30 or less than 25 and the waist-to-height ratio target of less than 0.5 (not controlled for type I error) at week 80 for the treatment-regimen estimand.
![An illustrated diagram from the Review Article "GLP-1 Receptor Agonists" that shows the physiologic effects of the incretin family of drugs. It shows that the three major insulinotropic peptides (glucagon-like peptide 1 [GLP-1], glucose-dependent insulinotropic peptide [GIP], and glucagon) are synthesized by several tissues, although the pancreas and the small intestine are major sources of the circulating forms. Synthesis begins with the 160–amino acid glucagon precursor, proglucagon (PG), which is differentially processed in the pancreas but not in the gut and brain. Proglucagon is cleaved to glucagon in the pancreas, and in the gut, four fragments having important functions are produced.](https://pbs.twimg.com/media/HQqrc91XYAAP60E.jpg?name=small&format=webp)
ALT An illustrated diagram from the Review Article "GLP-1 Receptor Agonists" that shows the physiologic effects of the incretin family of drugs. It shows that the three major insulinotropic peptides (glucagon-like peptide 1 [GLP-1], glucose-dependent insulinotropic peptide [GIP], and glucagon) are synthesized by several tissues, although the pancreas and the small intestine are major sources of the circulating forms. Synthesis begins with the 160–amino acid glucagon precursor, proglucagon (PG), which is differentially processed in the pancreas but not in the gut and brain. Proglucagon is cleaved to glucagon in the pancreas, and in the gut, four fragments having important functions are produced.





































